Royal Bank Of Canada Has Lowered Expectations for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck & Co., Inc. (NYSE:MRK) had its price target lowered by stock analysts at Royal Bank Of Canada from $150.00 to $145.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price points to a potential upside of 2.13% from the company’s previous close.

MRK has been the topic of several other research reports. Berenberg Bank upped their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Rothschild & Co Redburn lifted their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, July 6th. Morgan Stanley lowered their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. Finally, The Goldman Sachs Group boosted their target price on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Trading Down 2.4%

NYSE MRK opened at $141.97 on Monday. The firm has a market capitalization of $350.27 billion, a PE ratio of 45.31, a P/E/G ratio of 6.72 and a beta of 0.21. The stock’s 50 day moving average is $144.52 and its 200 day moving average is $128.73. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president directly owned 46,613 shares in the company, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MRK. Susquehanna Fundamental Investments LLC bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at approximately $11,470,000. Russell Investments Group Ltd. raised its holdings in Merck & Co., Inc. by 2.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock valued at $331,931,000 after buying an additional 51,393 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Merck & Co., Inc. by 7.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company’s stock worth $794,577,000 after buying an additional 402,011 shares during the last quarter. Talon Private Wealth LLC bought a new stake in Merck & Co., Inc. in the second quarter worth $995,000. Finally, Panagora Asset Management Inc. lifted its position in Merck & Co., Inc. by 410.5% in the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock worth $74,255,000 after buying an additional 567,249 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck will present first-time results from three pivotal Phase 3 oncology trials at the ESMO 2026 congress, alongside more than 90 additional abstracts covering over 20 tumor types. The disclosures could provide investors with evidence of pipeline progress and support long-term growth beyond the company’s existing portfolio. Merck ESMO 2026 announcement
• Positive Sentiment: Citigroup raised its price target for MRK to $145 from $125, although it maintained a neutral rating. The higher target reflects some improvement in the firm’s valuation view, even as the limited implied upside signals caution.
• Neutral Sentiment: Merck appointed Paul J. Diaz to its board of directors. The appointment adds healthcare-management experience but is unlikely to materially change near-term earnings expectations. Paul J. Diaz elected to Merck board
• Neutral Sentiment: Merck is scheduled to report third-quarter results in about two weeks. Analysts expect single-digit EPS growth, making the report and management’s guidance important catalysts for the stock. Merck upcoming earnings expectations
• Negative Sentiment: Jefferies cut its peak-sales forecast for remigromig by 60% after trial details showed smaller numerical vision improvements than an established competitor and raised safety concerns. Although the drug met the statistical non-inferiority threshold, the reduced commercial opportunity weighs on Merck’s growth outlook. Jefferies remigromig sales forecast cut
• Negative Sentiment: Erste Group modestly lowered its FY2026 and FY2027 EPS estimates, reinforcing caution around Merck’s earnings trajectory. The stock’s decline during the session appears consistent with investors focusing on these forecast reductions and remigromig concerns despite the positive oncology pipeline news.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.